<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-id journal-id-type="iso-abbrev">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23531324</article-id><article-id pub-id-type="pmc">3672692</article-id><article-id pub-id-type="publisher-id">cc12586</article-id><article-id pub-id-type="doi">10.1186/cc12586</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Quality of life and pruritus in patients with severe sepsis resuscitated with hydroxyethyl starch long-term follow-up of a randomised trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Wittbrodt</surname><given-names>Piotr</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>snajper2@yahoo.co.uk</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Haase</surname><given-names>Nicolai</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>Nicolai.Rosenkrantz.Segelcke.Haase@regionh.dk</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Butowska</surname><given-names>Dominika</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>butowska@yahoo.com</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Winding</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>robewind@rm.dk</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Poulsen</surname><given-names>Jesper B</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>jpoulsen@dadlnet.dk</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Perner</surname><given-names>Anders</given-names></name><email>Anders.Perner@regionh.dk</email></contrib><on-behalf-of>the 6S trial group and the Scandinavian Critical Care Trials Group<xref ref-type="corresp" rid="d33e63"/></on-behalf-of></contrib-group><aff id="I1"><label>1</label>Department of Anaesthesia and Intensive Care, Herning Hospital, Gl. Landevej 61, 7400 Herning, Denmark</aff><aff id="I2"><label>2</label>Department of Intensive Care, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark</aff><aff id="I3"><label>3</label>Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, 2100 Copenhagen, Denmark</aff><author-notes><corresp id="d33e63">the 6S trial group and the Scandinavian Critical Care Trials Group</corresp></author-notes><pub-date pub-type="ppub"><year>2013</year></pub-date><pub-date pub-type="epub"><day>25</day><month>2</month><year>2013</year></pub-date><volume>17</volume><issue>2</issue><fpage>R58</fpage><lpage>R58</lpage><history><date date-type="received"><day>10</day><month>10</month><year>2012</year></date><date date-type="rev-recd"><day>10</day><month>12</month><year>2012</year></date><date date-type="accepted"><day>20</day><month>2</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013 Wittbrodt et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Wittbrodt et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://ccforum.com/content/17/2/R58"/><abstract><sec><title>Introduction</title><p>The effects of hydroxyethyl starch (HES) on patient-centered outcome measures have not been fully described in patients with severe sepsis. We assessed health-related quality of life (HRQoL) and the occurrence of pruritus in patients with severe sepsis randomized to resuscitation with HES 130/0.42 or Ringer's acetate.</p></sec><sec><title>Methods</title><p>We did post hoc analyses of the Danish survivors (<italic>n </italic>= 295) of the 6S trial using mailed questionnaires on self-perceived HRQoL (Short Form (SF) - 36) and pruritus.</p></sec><sec><title>Results</title><p>Median 14 months (interquartile range 10 to 18) after randomization, 182 (61%) and 185 (62%) completed questionnaires were obtained for the assessment of HRQoL and pruritus, respectively. Responders were older than nonresponders, but characteristics at randomization of the responders in the HES vs. Ringer's groups were comparable. At follow-up, the patients in the HES group had lower mental component summary scores than those in the Ringer's group (median 45 (interquartile range 36 to 55) vs. 53 (39 to 60), <italic>P </italic>= 0.01). The group differences were mainly in the scales of vitality and mental health. There was no difference in the physical component summary scores between groups, but patients in the HES group scored worse in bodily pain. Forty-nine percent of patients allocated to HES had experienced pruritus at any time after ICU discharge compared to 43% of those allocated to Ringer's (relative risk 1.13, 95% confidence interval 0.83 to 1.55, <italic>P </italic>= 0.43).</p></sec><sec><title>Conclusions</title><p>At long-term follow-up patients with severe sepsis assigned to resuscitation with HES 130/0.42 had worse self-perceived HRQoL than those assigned to Ringer's acetate whereas there were no statistically significant differences in the occurrence of pruritus.</p></sec></abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Hydroxyethyl starch (HES) has been one of the most frequently used fluids for resuscitation in intensive care units (ICUs) worldwide [<xref ref-type="bibr" rid="B1">1</xref>]. However, recent trials of HES 130/0.38 to 0.45 (molecular weight/substitution grade) have shown increased frequency of adverse events and use of renal replacement therapy and blood products in general ICU patients in addition to increased mortality in patients with severe sepsis [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. Moreover, HES treatment has been shown to cause pruritus described as dose-dependent, delayed in onset and persistent [<xref ref-type="bibr" rid="B4">4</xref>]. Studies report pruritus occurrence in none to 55% of patients [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B12">12</xref>] and it is controversial if HES 130/0.38 to 0.45 causes less pruritus than the HES solutions with higher molecular weight and substitution grade [<xref ref-type="bibr" rid="B10">10</xref>]. The effects of HES 130/0.38 to 0.45 on patient-centered outcome measures have not been fully described in patients with severe sepsis. The purpose of this study was to assess self-perceived health-related quality of life (HRQoL), being one of the most important indicators of health care [<xref ref-type="bibr" rid="B13">13</xref>] and the occurrence of pruritus in long-term survivors of the Scandinavian Starch for Severe Sepsis/Septic Shock (6S) trial [<xref ref-type="bibr" rid="B3">3</xref>]. We hypothesized, that the HES group would have worse HRQoL and pruritus than those in the Ringers group.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Participants</title><p>The study population comprised the Danish survivors of the 6S trial as identified in the National Patient Registry. The 6S trial was investigator-initiated, multicenter, blinded, stratified, parallel-grouped using a computer-generated allocation sequence and centralized, blinded randomization. The inclusion and exclusion criteria are given in Additional file <xref ref-type="supplementary-material" rid="S1">1</xref> and the CONSORT diagram of the screening, randomization and the 90-day follow-up process appears in the original publication and in the study protocol [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. The participants in the 6S trial were randomly allocated to fluid resuscitation in the trial ICUs between December 2009 and November 2011 using either 6% HES 130/0.42 in Ringer's acetate (Tetraspan 6%, B Braun Medical, Melsungen, Germany) or Ringer's acetate (Sterofundin ISO, B Braun Medical). The unblinding of the trial occurred on 24 March 2012.</p><p>In March 2012, printed copies of the short form (SF)-36 and a self-composed pruritus questionnaire were sent to all the Danish survivors together with a letter explaining the purpose of the follow-up study. Nonresponders were contacted by telephone in May 2012. Consent was obtained at the inclusion in the 6S trial, and the post hoc analyses and renewed contact with the patients were approved by the Danish Medicines Agency and the Ethics Committee for the Capital Region of Denmark. At the time of contact, none of the patients knew the results of the 6S trial or which trial fluid they had received.</p></sec><sec><title>Assessment of HRQoL</title><p>The SF-36 comprises three levels: items (questions), scales scoring the items and main summary scores aggregating the scales - the physical and mental component summary (PCS and MCS) scores. It is a self-administered questionnaire consisting of 36 items measuring eight scales of health: physical functioning (PF), role of limitations due to physical health (RP), bodily pain (BP), general health perceptions (GH), vitality (VT), social functioning (SF), role of limitations due to emotional problems (RE), and mental health (MH). Since its creation in the early 1990s the questionnaire has been used and validated in different clinical settings including ICU patients [<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B17">17</xref>].</p><p>We used the Danish version of the questionnaire. To adapt the original (English, USA) version of SF-36, all the items have been translated as described by the International Quality of Life Assessment protocol [<xref ref-type="bibr" rid="B18">18</xref>] and validated in accordance with the local characteristics of the population [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>].</p></sec><sec><title>Assessment of pruritus</title><p>Pruritus was assessed by a self-composed questionnaire (see Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>) including a visual analog scale (VAS) to describe the intensity of pruritus. We asked about the occurrence of pruritus in the past two days as well as at any time after the index ICU admission, actions taken to relieve pruritus, specifying the use of ointments, tablets and contact to general practitioner, dermatologist or other.</p></sec><sec><title>Statistical analyses</title><p>The investigator (PW) analyzing the data was blinded to the assigned trial fluids. The predefined primary outcome measures were the PCS and MCS scores for the HRQoL part and any pruritus after ICU discharge ('Yes' in either question 1 or 2, see Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>) for the pruritus part. The secondary outcome measures were the scale scores for the HRQoL part, pruritus in the last 48 hours, the severity of pruritus and actions taken against pruritus.</p><p>SF-36 was scored according to the manual [<xref ref-type="bibr" rid="B21">21</xref>]. Three different methods were applied to assess the influence of missing data on the results: 1) a complete-case analysis rejecting scales where <italic>any </italic>item was missing, 2) analyses of imputed data using missing data estimation (MDE) software provided by Quality Metrics Inc. (Lincoln, RI, USA) and 3) two best/worst-case analyses where missing answers in the HES group were set to the worst possible answer and missing answers in the Ringer's group were set to the best possible answer and vice versa. The latter analyses were done after unblinding of the investigator performing the analyses.</p><p>All the obtained scores for the eight scales and PCS and MCS scores were described as median values with interquartile ranges (IQR) and compared between the trial groups using the Mann-Whitney U test. The response consistency index (RCI) was calculated to assess the potential inconsistencies within the relevant items of the SF-36. The scales were evaluated for internal consistency by Cronbach's alpha coefficients and for the discriminate validity between the mental and the physical components.</p><p>To evaluate the occurrence of pruritus in total, we described the percentage of affirmative answers in questions 1 and 2 of the questionnaire, while the severity was assessed by the median scores on VAS and compared between the treatment groups using the chi-square test and Mann-Whitney U test, respectively. The answers to questions concerning actions taken against pruritus were described as percentages and compared between groups using chi-square testing. The statistical analyses were done using Health Outcomes Scoring Software (Quality Metrics Inc.), SPSS Statistics version 20.0 (IBM, Armonk, NY, USA) and SAS 9.2 (SAS Institute Inc., Cary, NC, USA). <italic>P </italic>values &#x0003c; 0.05 were considered significant.</p></sec></sec><sec sec-type="results"><title>Results</title><p>The inclusion process yielded 182 (HRQoL) and 185 (pruritus) valid responses from a total of 295 different patients median 14 months (IQR 9 to 18) after randomization. The response rates were 61% for HRQoL and 62% for pruritus (Figure <xref ref-type="fig" rid="F1">1</xref>). The responders were older and more had shock at randomization compared to the nonresponders (Table <xref ref-type="table" rid="T1">1</xref>). Among the responders the baseline characteristics at randomization and time to follow-up (Table <xref ref-type="table" rid="T2">2</xref>) were comparable between patients assigned to HES and those assigned to Ringer's.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Flowchart of the data collection process</bold>. Reasons for nonresponding were as follows: eight were too sick to answer (four in each group), six were unwilling to participate and for the remaining ninety-one patients our attempts to reach them by telephone were unsuccessful.</p></caption><graphic xlink:href="cc12586-1"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Characteristics at randomization of responders and nonresponders.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="center">Responders<break/>(<italic>n </italic>= 190)</th><th align="center">Nonresponders<break/>(<italic>n </italic>= 105)</th><th align="center"><italic>P </italic>value</th></tr></thead><tbody><tr><td align="left"><bold>Allocated to HES - n (%)</bold></td><td align="center">98 (52)</td><td align="center">42 (40)</td><td align="center">0.06</td></tr><tr><td align="left"><bold>Age - years</bold></td><td align="center">66 (59-74)</td><td align="center">56 (49-66)</td><td align="center">&#x0003c; 0.0001</td></tr><tr><td align="left"><bold>Male gender - no. (%)</bold></td><td align="center">105 (55)</td><td align="center">65 (62)</td><td align="center">0.27</td></tr><tr><td align="left"><bold>Included at university hospital - no. (%)</bold></td><td align="center">71 (37)</td><td align="center">37 (35)</td><td align="center">0.72</td></tr><tr><td align="left"><bold>Surgery<sup>1 </sup>- no. (%)</bold></td><td/><td/><td/></tr><tr><td align="left">&#x02003;Emergency</td><td align="center">64 (34)</td><td align="center">29 (28)</td><td align="center">0.28</td></tr><tr><td align="left">&#x02003;Elective</td><td align="center">24 (13)</td><td align="center">10 (10)</td><td align="center">0.42</td></tr><tr><td align="left"><bold>Source of sepsis<sup>2 </sup>- no. (%)</bold></td><td/><td/><td/></tr><tr><td align="left">&#x02003;Lungs</td><td align="center">80 (42)</td><td align="center">59 (56)</td><td align="center">-</td></tr><tr><td align="left">&#x02003;Abdomen</td><td align="center">73 (38)</td><td align="center">24 (23)</td><td align="center">-</td></tr><tr><td align="left">&#x02003;Urinary tract</td><td align="center">26 (14)</td><td align="center">15 (14)</td><td align="center">-</td></tr><tr><td align="left">&#x02003;Soft tissue</td><td align="center">23 (12)</td><td align="center">15 (14)</td><td align="center">-</td></tr><tr><td align="left">&#x02003;Other</td><td align="center">22 (12)</td><td align="center">8 (8)</td><td align="center">-</td></tr><tr><td align="left"><bold>SAPS II</bold></td><td align="center">49 (38-58)</td><td align="center">47 (34-55)</td><td align="center">0.16</td></tr><tr><td align="left"><bold>SOFA score<sup>3</sup></bold></td><td align="center">7 (5-9)</td><td align="center">7 (5-9)</td><td align="center">0.64</td></tr><tr><td align="left"><bold>Shock<sup>4 </sup>- no. (%)</bold></td><td align="center">160 (84)</td><td align="center">76 (72)</td><td align="center">0.02</td></tr><tr><td align="left"><bold>Acute kidney injury<sup>5 </sup>- no. (%)</bold></td><td align="center">71 (37)</td><td align="center">34 (32)</td><td align="center">0.39</td></tr><tr><td align="left"><bold>Mechanical ventilation - no. (%)</bold></td><td align="center">98 (52)</td><td align="center">59 (56)</td><td align="center">0.45</td></tr><tr><td align="left"><bold>Comorbidities</bold></td><td/><td/><td/></tr><tr><td align="left">&#x02003;Diabetes mellitus - no. (%)</td><td align="center">28 (15)</td><td align="center">23 (22)</td><td align="center">0.12</td></tr><tr><td align="left">&#x02003;Arterial hypertension - no. (%)</td><td align="center">81 (43)</td><td align="center">33 (31)</td><td align="center">0.06</td></tr><tr><td align="left">&#x02003;Chronic renal disease<sup>6 </sup>- no. (%)</td><td align="center">23 (13)</td><td align="center">20 (21)</td><td align="center">0.11</td></tr><tr><td align="left">&#x02003;Hematological malignancy - no. (%)</td><td align="center">15 (8)</td><td align="center">3 (3)</td><td align="center">0.08</td></tr><tr><td align="left"><bold>Previous admission for - no. (%)</bold></td><td/><td/><td/></tr><tr><td align="left">&#x02003;Heart failure or myocardial infarction</td><td align="center">22 (12)</td><td align="center">9 (9)</td><td align="center">0.42</td></tr><tr><td align="left">&#x02003;Stroke</td><td align="center">13 (7)</td><td align="center">11 (10)</td><td align="center">0.27</td></tr><tr><td align="left">&#x02003;Asthma or COPD</td><td align="center">24 (13)</td><td align="center">15 (14)</td><td align="center">0.69</td></tr></tbody></table><table-wrap-foot><p><sup>1</sup>Numbers are for patients who underwent surgery during the index hospitalization, but before randomization. <sup>2</sup>Some patients had more than one source of infection. The 'other' category included sepsis from a vascular catheter-related infection, meningitis, or endocarditis, as well as sepsis from unknown sources. <sup>3</sup>The SOFA scoring was modified because cerebral failure was not assessed. <sup>4</sup>Shock at randomization was defined as a mean arterial pressure of less than 70 mm Hg, the need for ongoing treatment with vasopressor or inotropic agents, or a plasma lactate level of more than 4.0 mmol per liter in the hour before randomization. <sup>5</sup>Acute kidney injury was defined as a renal SOFA score of 2 or higher (plasma creatinine level &#x0003e; 170 &#x003bc;mol/l (1.9 mg/dl) or urinary output &#x0003c; 500 ml/d). <sup>6</sup>Chronic renal disease was defined as a preadmission plasma creatinine &#x0003e; 100 &#x003bc;mol/l (1.2 mg/dl). HES, hydroxyethyl starch; SAPS, simplified acute physiology score; SOFA, sequential organ failure assessment, COPD, chronic obstructive pulmonary disease.</p></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Characteristics at randomization of patients who responded to at least one of the questionnaires.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="center">HES 130/0.42<break/>(<italic>n </italic>= 98)</th><th align="center">Ringer's acetate<break/>(<italic>n </italic>= 92)</th></tr></thead><tbody><tr><td align="left"><bold>Time to follow-up - months</bold></td><td align="center">13 (9-17)</td><td align="center">14 (10-18)</td></tr><tr><td align="left"><bold>Age - years</bold></td><td align="center">66 (59-74)</td><td align="center">66 (58-75)</td></tr><tr><td align="left"><bold>Male gender - no. (%)</bold></td><td align="center">52 (53)</td><td align="center">53 (58)</td></tr><tr><td align="left"><bold>Included at university hospital - no. (%)</bold></td><td align="center">35 (36)</td><td align="center">36 (39)</td></tr><tr><td align="left"><bold>Surgery<sup>1 </sup>- no. (%)</bold></td><td/><td/></tr><tr><td align="left">&#x02003;Emergency</td><td align="center">31 (32)</td><td align="center">33 (36)</td></tr><tr><td align="left">&#x02003;Elective</td><td align="center">7 (7)</td><td align="center">17 (18)</td></tr><tr><td align="left"><bold>Source of ICU admittance - no. (%)</bold></td><td/><td/></tr><tr><td align="left">&#x02003;Emergency department</td><td align="center">32 (33)</td><td align="center">21 (23)</td></tr><tr><td align="left">&#x02003;General ward</td><td align="center">40 (41)</td><td align="center">39 (42)</td></tr><tr><td align="left">&#x02003;Operating or recovery room</td><td align="center">17 (17)</td><td align="center">21 (23)</td></tr><tr><td align="left">&#x02003;Other ICU in the same hospital</td><td align="center">2 (2)</td><td align="center">2 (2)</td></tr><tr><td align="left">&#x02003;Other hospital</td><td align="center">7 (7)</td><td align="center">9 (10)</td></tr><tr><td align="left"><bold>Source of sepsis<sup>2 </sup>- no. (%)</bold></td><td/><td/></tr><tr><td align="left">&#x02003;Lungs</td><td align="center">42 (43)</td><td align="center">38 (41)</td></tr><tr><td align="left">&#x02003;Abdomen</td><td align="center">40 (41)</td><td align="center">33 (36)</td></tr><tr><td align="left">&#x02003;Urinary tract</td><td align="center">13 (13)</td><td align="center">13 (14)</td></tr><tr><td align="left">&#x02003;Soft tissue</td><td align="center">9 (9)</td><td align="center">14 (15)</td></tr><tr><td align="left">&#x02003;Other</td><td align="center">10 (10)</td><td align="center">12 (13)</td></tr><tr><td align="left"><bold>Positive culture from blood or a sterile site - no. (%)</bold></td><td align="center">17 (17)</td><td align="center">11 (12)</td></tr><tr><td align="left"><bold>Time from ICU admission to randomization - hours</bold></td><td align="center">3 (1-11)</td><td align="center">3 (1-14)</td></tr><tr><td align="left"><bold>SAPS II</bold></td><td align="center">48 (36-58)</td><td align="center">50 (38-59)</td></tr><tr><td align="left"><bold>SOFA score<sup>3</sup></bold></td><td align="center">7 (5-9)</td><td align="center">7 (5-9)</td></tr><tr><td align="left"><bold>Shock<sup>4 </sup>- no. (%)</bold></td><td align="center">80 (82)</td><td align="center">80 (87)</td></tr><tr><td align="left"><bold>Acute kidney injury<sup>5 </sup>- no. (%)</bold></td><td align="center">36 (37)</td><td align="center">35 (38)</td></tr><tr><td align="left"><bold>Mechanical ventilation - no. (%)</bold></td><td align="center">44 (45)</td><td align="center">54 (59)</td></tr><tr><td align="left"><bold>Comorbidities</bold></td><td/><td/></tr><tr><td align="left">&#x02003;Diabetes mellitus - no. (%)</td><td align="center">12 (12)</td><td align="center">16 (17)</td></tr><tr><td align="left">&#x02003;Arterial hypertension - no. (%)</td><td align="center">42 (43)</td><td align="center">39 (42)</td></tr><tr><td align="left">&#x02003;Chronic renal disease<sup>6 </sup>- no. (%)</td><td align="center">9 (10)</td><td align="center">14 (17)</td></tr><tr><td align="left">&#x02003;Hematological malignancy - no. (%)</td><td align="center">6 (6)</td><td align="center">9 (10)</td></tr><tr><td align="left"><bold>Previous admission for - no. (%)</bold></td><td/><td/></tr><tr><td align="left">&#x02003;Heart failure or myocardial infarction</td><td align="center">10 (10)</td><td align="center">12 (13)</td></tr><tr><td align="left">&#x02003;Stroke</td><td align="center">7 (7)</td><td align="center">6 (7)</td></tr><tr><td align="left">&#x02003;Asthma or COPD</td><td align="center">12 (12)</td><td align="center">12 (13)</td></tr><tr><td align="left"><bold>Any ventilation in the ICU, n (%)</bold></td><td align="center">71 (72)</td><td align="center">72 (78)</td></tr><tr><td align="left"><bold>Days in ventilator if treated, median (IQR)</bold></td><td align="center">6 (3-14)</td><td align="center">5 (3-12)</td></tr><tr><td align="left"><bold>Any renal replacement therapy dialysis in the ICU, n (%)</bold></td><td align="center">18 (18)</td><td align="center">15 (16)</td></tr><tr><td align="left"><bold>Days in renal replacement therapy if treated, median (IQR)</bold></td><td align="center">7 (3-22)</td><td align="center">10 (6-22)</td></tr><tr><td align="left"><bold>Days in ICU, median (IQR)</bold></td><td align="center">6 (3-14)</td><td align="center">8 (4-14)</td></tr><tr><td align="left"><bold>Days in hospital in the 90 days follow-up period, median (IQR)</bold></td><td align="center">32 (20-50)</td><td align="center">30 (20-53)</td></tr></tbody></table><table-wrap-foot><p><sup>1</sup>Numbers are for patients who underwent surgery during the index hospitalization, but before randomization. <sup>2</sup>Some patients had more than one source of infection. The 'other' category included sepsis from a vascular catheter-related infection, meningitis, or endocarditis, as well as sepsis from unknown sources. <sup>3</sup>The SOFA scoring was modified because cerebral failure was not assessed. <sup>4</sup>Shock at randomization was defined as a mean arterial pressure of less than 70 mm Hg, the need for ongoing treatment with vasopressor or inotropic agents, or a plasma lactate level of more than 4.0 mmol per liter in the hour before randomization. <sup>5</sup>Acute kidney injury was defined as a renal SOFA score of 2 or higher (plasma creatinine level &#x0003e; 170 &#x003bc;mol/l (1.9 mg/dl) or urinary output &#x0003c; 500 ml/d). <sup>6</sup>Chronic renal disease was defined as a preadmission plasma creatinine &#x0003e; 100 &#x003bc;mol/l (1.2 mg/dl). HES, hydroxyethyl starch; SAPS, simplified acute physiology score; SOFA, sequential organ failure assessment, COPD, chronic obstructive pulmonary disease; IQR, interquartile range.</p></table-wrap-foot></table-wrap><sec><title>Data quality</title><p>Completeness of data in SF-36, defined as completed responses divided by the total possible number of responses was 96%. In the cases of twenty patients, it was impossible to calculate all the scales. All the obtained responses were within range for the individual items. Eighty-four percent of the responses were defined as consistent using RCI, with a total of 30 questionnaires containing items with sporadic inconsistencies (in one or two questions). We were able to score all the scales in 90% of the cases without using any imputation of missing data, which increased to 97% after imputation of missing data.</p><p>The internal consistency of the items, defined by correlation of 0.4 with their hypothesized scale was 100%. The item MH4 'have you felt downhearted and blue' correlated better (0.61) with VT than with its hypothesized scale MH. All the other items showed highest correlations with their designed scales. The reliability estimates, defining the correlation grade, (with the exception of PF) ranged from 0.83 (MH) to 0.89 (RP); PF reached the value of 0.94.</p><p>Most of the questionnaires evaluating pruritus were complete (0.5 to 11% missing answers), and there were no inconsistencies within the questionnaires.</p></sec><sec><title>Health-related quality of life</title><p>The patients allocated to HES had significantly lower MCS score, bodily pain, vitality, social function and mental health than those allocated to Ringer's (Table <xref ref-type="table" rid="T3">3</xref>). There were no statistical differences in PCS scores between the intervention groups. Comparable results were observed in the complete-case analyses with the exception of social function (<italic>P </italic>= 0.07 without imputation). The best/worst-case analyses did not change the direction of the intervention effect, but only mental health remained statistically different when the missing values in the HES group were substituted with the best possible score and those in the Ringer's group the worst possible score (see Table S1 in Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>).</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Health-related quality of life in patients with severe sepsis allocated to HES 130/0</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="left" colspan="5">Imputation dataset</th><th align="left" colspan="5">Complete case dataset</th></tr><tr><th/><th colspan="10"><hr/></th></tr><tr><th/><th align="left" colspan="2">HES group</th><th align="left" colspan="3">Ringer's group</th><th align="left" colspan="2">HES group</th><th align="left" colspan="3">Ringer's group</th></tr><tr><th align="left">Scale</th><th align="left">N</th><th align="left">IQR</th><th align="left">N</th><th align="left">IQR</th><th align="left"><italic>P </italic>value</th><th align="center">N</th><th align="left">IQR</th><th align="left">N</th><th align="left">IQR</th><th align="left"><italic>P </italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="11"><bold>Primary outcomes</bold></td></tr><tr><td align="left">PCS</td><td align="left">88</td><td align="left">37 (29-48)</td><td align="left">83</td><td align="left">40 (32-51)</td><td align="left">0.23</td><td align="center">74</td><td align="left">38 (29-48)</td><td align="left">63</td><td align="left">42 (33-52)</td><td align="left">0.15</td></tr><tr><td align="left">MCS</td><td align="left">88</td><td align="left">45 (36-55)</td><td align="left">83</td><td align="left">53 (39-60)</td><td align="left">0.01</td><td align="center">74</td><td align="left">46 (35-56)</td><td align="left">63</td><td align="left">54 (41-59)</td><td align="left">0.02</td></tr><tr><td align="left" colspan="5"><bold>Secondary outcomes</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">PF</td><td align="left">94</td><td align="left">50 (20-75)</td><td align="left">86</td><td align="left">65 (30-85)</td><td align="left">0.17</td><td align="center">91</td><td align="left">50 (20-75)</td><td align="left">81</td><td align="left">65 (30-85)</td><td align="left">0.23</td></tr><tr><td align="left">RP</td><td align="left">87</td><td align="left">0 (0-75)</td><td align="left">82</td><td align="left">13 (0-75)</td><td align="left">0.63</td><td align="center">85</td><td align="left">0 (0-75)</td><td align="left">79</td><td align="left">25 (0-75)</td><td align="left">0.46</td></tr><tr><td align="left">BP</td><td align="left">95</td><td align="left">52 (31-84)</td><td align="left">86</td><td align="left">73 (42-100)</td><td align="left">0.007</td><td align="center">91</td><td align="left">52 (31-84)</td><td align="left">83</td><td align="left">72 (42-100)</td><td align="left">0.02</td></tr><tr><td align="left">GH</td><td align="left">95</td><td align="left">42 (30-62)</td><td align="left">87</td><td align="left">52 (25-72)</td><td align="left">0.35</td><td align="center">86</td><td align="left">41 (30-62)</td><td align="left">80</td><td align="left">52 (30-72)</td><td align="left">0.19</td></tr><tr><td align="left">VT</td><td align="left">94</td><td align="left">45 (29-60)</td><td align="left">85</td><td align="left">55 (35-75)</td><td align="left">0.008</td><td align="center">92</td><td align="left">45 (28-60)</td><td align="left">82</td><td align="left">55 (35-75)</td><td align="left">0.004</td></tr><tr><td align="left">SF</td><td align="left">93</td><td align="left">75 (38-100)</td><td align="left">86</td><td align="left">88 (63-100)</td><td align="left">0.03</td><td align="center">88</td><td align="left">75 (38-100)</td><td align="left">81</td><td align="left">75 (63-100)</td><td align="left">0.07</td></tr><tr><td align="left">RE</td><td align="left">87</td><td align="left">33 (0-100)</td><td align="left">81</td><td align="left">67 (0-100)</td><td align="left">0.19</td><td align="center">84</td><td align="left">33 (0-100)</td><td align="left">78</td><td align="left">67 (0-100)</td><td align="left">0.18</td></tr><tr><td align="left">MH</td><td align="left">93</td><td align="left">64 (52-82)</td><td align="left">86</td><td align="left">80 (60-92)</td><td align="left">0.004</td><td align="center">91</td><td align="left">64 (52-84)</td><td align="left">85</td><td align="left">80 (60-92)</td><td align="left">0.006</td></tr></tbody></table><table-wrap-foot><p>Data from the imputed and complete case datasets are given. Values are medians and interquartile ranges (IQR). <italic>N </italic>= number of patient where the scales could be calculated. HES, hydroxyethyl starch; PCS, physical component summary; MCS, mental component summary; PF, physical functioning; RP, role physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role emotional; MH, mental health.</p></table-wrap-foot></table-wrap></sec><sec><title>Pruritus</title><p>There were no statistical significant differences between the groups in the occurrence or severity of pruritus (Table <xref ref-type="table" rid="T4">4</xref>). More patients in the HES group had used ointments or tablets against pruritus than those in the Ringer's group (Table <xref ref-type="table" rid="T4">4</xref>). Seven patients (six in the Ringers group) indicated that they had pruritus in the last 72 hours prior to answering the questionnaire, but not before.</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Pruritus in patients with severe sepsis allocated to HES 130/0</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="center">HES<break/>130/0.42</th><th align="center">Ringer's acetate</th><th align="center">Relative risk (95%CI)</th><th align="center"><italic>P </italic>value</th></tr></thead><tbody><tr><td align="left"><bold>Primary outcome</bold></td><td/><td/><td/><td/></tr><tr><td align="left">Pruritus at any time after discharge, n/N (%)</td><td align="center">47/96 (49)</td><td align="center">38/88 (43)</td><td align="center">1.13 (0.83-1.55)</td><td align="center">0.43</td></tr><tr><td align="left"><bold>Secondary outcomes</bold></td><td/><td/><td/><td/></tr><tr><td align="left">Pruritus in the last 48 hours, n/N (%)</td><td align="center">31/95 (33)</td><td align="center">24/89 (27)</td><td align="center">1.21 (0.77-1.89)</td><td align="center">0.40</td></tr><tr><td align="left">VAS score, median (IQR)*</td><td align="center">4.5 (3.5-5.5)</td><td align="center">3.5 (2.0-6.5)</td><td align="center">-</td><td align="center">0.28</td></tr><tr><td align="left">Action taken against pruritus n/N (%)</td><td align="center">36/96 (37)</td><td align="center">20/88 (23)</td><td align="center">1.65 (1.04-2.62)</td><td align="center">0.03</td></tr><tr><td align="left">&#x02003;Use of ointment/tablets n/N (%)</td><td align="center">36/96 (37)</td><td align="center">19/88 (21)</td><td align="center">1.74 (1.08-2.79)</td><td align="center">0.02</td></tr><tr><td align="left">&#x02003;Consulted GP n/N (%)</td><td align="center">11/96 (11)</td><td align="center">7/88 (8)</td><td align="center">1.26 (0.53-2.99)</td><td align="center">0.60</td></tr><tr><td align="left">&#x02003;Consulted dermatologist n/N (%)</td><td align="center">2/96 (2)</td><td align="center">5/88 (6)</td><td align="center">0.37 (0.07-1.84)</td><td align="center">0.20</td></tr></tbody></table><table-wrap-foot><p><italic>N </italic>= number of patients in the treatment group. <italic>n </italic>= number of cases. *Medians are for those who had pruritus within the last 48 hours. HES, hydroxyethyl starch; VAS, visual analogue scale; IQR, interquartile range, GP, general practitioner.</p></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>In post hoc analyses of this multicenter, blinded, randomized trial of fluid resuscitation in severe sepsis, HRQoL at long-term follow-up was lower in patients allocated to HES 130/0.42 compared to those allocated to Ringer's acetate. The differences in HRQoL were observed in the MCS score, three scales describing the mental health and in one scale describing the physical health of the patients.</p><p>To the best of our knowledge this is the first report on HRQoL after fluid therapy with HES. We can only speculate on the mechanisms by which HES adversely affected HRQoL. As the patients allocated to HES had more bleeding episodes, higher use of blood products and renal replacement therapy and fewer days out of hospital in the 90-day trial period after randomization, all these factors may have contributed to lower HRQoL compared with patients in the Ringer's group [<xref ref-type="bibr" rid="B3">3</xref>]. In addition, long-term toxic effects of HES deposited in kidney, liver and bone marrow have been documented [<xref ref-type="bibr" rid="B22">22</xref>-<xref ref-type="bibr" rid="B25">25</xref>]. HES does not seem to cross the intact blood-brain barrier in animal models, however, it does accumulate in the peripheral nerves [<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. These toxic effects may affect the general health and thereby HRQoL of the patients, but we do not have data to substantiate such effects in our patients.</p><p>There were no statistically significant differences in the occurrence or severity of pruritus between the two intervention groups. The point estimates did favor the Ringer's group and more patients in the HES group had used medications against pruritus. That HES may cause pruritus also in ICU patients is supported by data from the CHEST trial, where HES 130/0.4 doubled the occurrence of pruritus compared to saline in general ICU patients [<xref ref-type="bibr" rid="B2">2</xref>]. It is noteworthy that a considerable number of patients in the Ringer's group reported pruritus in our study, suggesting that this is very frequent in survivors of severe sepsis. We observed many more patients with pruritus than in the CHEST and CRYSTMAS trials [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. The reasons for these differences may be due to differences in the timing, methods/questionnaires used to capture pruritus and to the different HES doses and patient populations in these trials. There are no details on the methods for pruritus assessment in the reports of the CHEST and CRYSTMAS trials.</p><p>The PCS and MCS scores observed here are within the range of those observed in other studies of HRQoL using SF-36 in long-term survivors of sepsis [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. More importantly, the PCS and MCS scores observed are well below those in the general population underlining the importance of HRQoL as an outcome measure in patients with severe sepsis in general and in trials in particular. The latter is substantiated by our observation of differences in HRQoL between patients in the two intervention groups.</p><p>There are several strengths to this study. The risk of bias was minimized by preparing the analysis plan before the analyses were done and both patients and the investigator analyzing the data were blinded to the intervention. Also the intervention groups were comparable at randomization. We used a validated tool to assess HRQoL, obtained good data quality and the results were comparable in the analyses of the imputed and complete-case datasets.</p><p>The study has several limitations. These were post hoc analyses of the Danish survivors only. We made contact with patients at the same time point, so that the follow-up time varied. Only 60% of the survivors responded and these patients were older and more had shock at baseline than the nonresponders. We cannot know if any of these limitations introduced bias. In 10% of the responses not all the scales were computable. As any missing data introduce uncertainty, we based our analyses on the currently recommended statistical approach [<xref ref-type="bibr" rid="B29">29</xref>], which is to impute data rather than to trust the complete-case analyses. The imputation lowered the number of cases with missing data to 3%, which likely minimized the potential bias. In addition, the best/worst-case analysis, which is the most conservative approach, did not change the direction of the intervention effect, but only the difference observed in MH remained significant when the missing data in the HES group were given the best possible score and those in the Ringer's group the worst possible score. It is unclear which magnitude of difference in SF-36 scores represents a meaningful difference for patients [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>]. Therefore, we cannot know if the observed differences in HRQoL mattered to the patients. Finally, our pruritus questionnaire has not been validated and we observed frequencies of pruritus that were much higher than those in the other trials of HES in ICU patients as described above.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Patients with severe sepsis assigned to resuscitation with HES 130/0.42 had worse self-perceived HRQoL at long-term follow-up than those who received Ringer's acetate, whereas there were no statistically significant differences in the occurrence of pruritus between the intervention groups. As these data add to the growing amount of evidence of worse outcome with HES in patients with severe sepsis, we recommend not using HES for these patients.</p></sec><sec><title>Key messages</title><p>&#x02022; The study showed that survivors of severe sepsis treated with hydroxyethyl starch scored significantly lower in SF-36 than those treated with Ringer's solution. The differences were seen in the mental component summary score, and the vitality, mental health, social function and bodily pain scales.</p><p>&#x02022; The differences in frequency and severity of pruritus between the HES and Ringer's group were not statistically significant.</p><p>&#x02022; Pruritus was very frequent in the sepsis survivors in the present trial.</p></sec><sec><title>Abbreviations</title><p>6S: Scandinavian Starch for Severe Sepsis/Septic Shock; BP: bodily pain; GH: general health; HES: hydroxyethyl starch; HRQoL: health-related quality of life; ICU: intensive care unit; IQR: interquartile range; MCS: mental component summary; MDE: missing data estimation; MH: mental health; PCS: physical component summary; PF: physical functioning; RCI: response consistency index; RE: role emotional; RP: role physical; SF-36: short form-36; SF: social functioning; VAS: visual analog scale; VT: vitality.</p></sec><sec><title>Competing interests</title><p>The 6S trial was funded by the Danish Strategic Research Council, the Danish Research Council and Rigshospitalet and supported by B Braun Medical AG. The Department of Intensive Care, Rigshospitalet receives research funds from Fresenius Kabi. Neither of these had any influence on the trial protocol or conduct nor data analyses or reporting.</p></sec><sec><title>Authors' contributions</title><p>PW, NH and AP conceived and designed the study. PW and DB acquired the data. PW, NH, DB and AP analyzed and interpreted the data. PW drafted the manuscript. AP, NH, JBP, RW and DB critically revised the manuscript for important intellectual content. RW and PW provided administrative, technical, and material support. AP supervised the study. All of the above stated authors have read and approved the manuscript for publication. The 6S trial group was responsible for the original randomized controlled trial.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>6S inclusion and exclusion criteria, best/worst-case analyses and pruritus questionnaire</bold>.</p></caption><media xlink:href="cc12586-S1.DOC"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><sec><title>Acknowledgements</title><sec><title>The 6S trial investigators</title><p><bold><italic>Steering Committee</italic></bold>: Anders Perner (Chair), Nicolai Haase, Anne B. Guttormsen, Jyrki Tenhunen, Gudmundur Klemenzson, Anders &#x000c5;neman and J&#x000f8;rn Wetterslev. <bold><italic>Management Committee</italic></bold>: Anders Perner (Chair), Nicolai Haase and J&#x000f8;rn Wetterslev. <bold><italic>Scientific Committee</italic></bold>: Simon Finfer, Andre Vercueil, Lars S. Rasmussen and Frank Brunkhorst. <bold><italic>Data Monitoring and Safety Committee</italic></bold>: Daniel De Backer (Chair), Peter Dalgaard and Kathy Rowan. <bold><italic>Trial site investigators (in Denmark unless otherwise specified)</italic></bold>: Rigshospitalet: A. Perner, N. Haase, M. N. Kj&#x000e6;r, K. R. Uhre, V. Knudsen, V. Christiansen, A. Schulze, J. Wiis, J. O. White, K. Thornberg, L. Quist, F. Sj&#x000f8;vall, N. Wesche, N. Reiter, I. L. Jarnvig, N&#x000e6;stved Hospital: K. R. Madsen, A. L. Kj&#x000e6;ldgaard, M. L. Fabritius, F. Mondrup, K. F. Sommer, L. F. Pedersen, Bispebjerg Hospital: M. H. M&#x000f8;ller, F. C. Pott, J. A. Petersen, A. Lindhardt, K. M&#x000f8;ller, A. Haraldson, C. Pedersen, Holb&#x000e6;k Hospital: H. H. B&#x000fc;low, J. M. Elkj&#x000e6;r, T. P. M&#x000f8;ller, L. H. Andersen, L. B. Holst, J. F. Schmidt, S. T. Nielsen, F. P. Treschow, M. Overgaard, H. Ahlstr&#x000f8;m, S. Grangaard, J. H. Bruun, S. Larsen, K&#x000f8;ge Hospital: L. M. Poulsen, M.V. Madsen, B. Bang, Glostrup Hospital: A. Bendtsen, Herning Hospital R. Winding, K. V. Jepsen, S. Haubjerg, N. Dey, J. Hj&#x000f8;rringsgaard, Hvidovre Hospital: M. Steensen, J. Nielsen, C. Albek, S. Petersen, A. Christensen, A. Kristensen, Vejle Hospital: P.Berezowicz, Herlev Hospital: P. S&#x000f8;e-Jensen, H. Tousi, Hiller&#x000f8;d Hospital: M. Bestle, K. Nielsen, T. Kold, K. Grundahl, Stavanger University Hospital, Norway: K. Strand, O. Larsen, Slagelse Hospital: S. Iversen, O. Sch&#x000f8;idt, Hj&#x000f8;rring Hospital: M. Pawlowicz, M. Kruse, H. S. Rasmussen, L. O. Nielsen, Haukeland University Hospital, Bergen, Norway: A. B. Guttormsen, B. Sj&#x000f8;b&#x000f8;, S&#x000f8;nderborg Hospital: S. Leivdal, Troms&#x000f8; University Hospital, Norway: L. M. Ytreb&#x000f8;, Tampere University Hospital, Finland: J. Tenhunen, S. Karlsson, A. Kukkurainen, S. Kortelainen, M. L. Peltola, S. Varila, Gentofte Hospital: K. Thormar, P. M. B&#x000e5;dst&#x000f8;l&#x000f8;kken, Landspitali, Reykjavik, Iceland: G. Klemenzson, S. Karason, Helsinki University Hospital, Finland: V. Pettil&#x000e4;, M. Kaukonen, L. Pettil&#x000e4;, S. Sutinen, Odense University Hospital: M. Carlson, N. H. Lassen, U. L. Larsen, K. D. Jung, Holstebro Hospital: C. Kancir, Kuopio University Hospital, Finland: J. Rutanen, E. Ruokonen, S. Rissanen, K. Kontra, Trondheim University Hospital, Norway: P. Klepstad, Esbjerg Hospital: R. E. Berthelsen, K. D. B&#x000f8;dker, B. Dilling.</p></sec></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Finfer</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Taylor</surname><given-names>C</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name><name><surname>Billot</surname><given-names>L</given-names></name><name><surname>Cook</surname><given-names>D</given-names></name><name><surname>Du</surname><given-names>B</given-names></name><name><surname>McArthur</surname><given-names>C</given-names></name><name><surname>Myburgh</surname><given-names>J</given-names></name><article-title>Resuscitation fluid use in critically ill adults: an international cross-sectional study in 391 intensive care units</article-title><source>Crit Care</source><year>2010</year><volume>14</volume><fpage>R185</fpage><pub-id pub-id-type="doi">10.1186/cc9293</pub-id><pub-id pub-id-type="pmid">20950434</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Myburgh</surname><given-names>JA</given-names></name><name><surname>Finfer</surname><given-names>S</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name><name><surname>Billot</surname><given-names>L</given-names></name><name><surname>Cass</surname><given-names>A</given-names></name><name><surname>Gattas</surname><given-names>D</given-names></name><name><surname>Glass</surname><given-names>P</given-names></name><name><surname>Lipman</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>McArthur</surname><given-names>C</given-names></name><name><surname>McGuinness</surname><given-names>S</given-names></name><name><surname>Rajbhandari</surname><given-names>D</given-names></name><name><surname>Taylor</surname><given-names>CB</given-names></name><name><surname>Webb</surname><given-names>SA</given-names></name><collab>CHEST Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group</collab><article-title>Hydroxyethyl starch or saline for fluid resuscitation in intensive care</article-title><source>N Engl J Med</source><year>2012</year><volume>367</volume><fpage>1901</fpage><lpage>1911</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1209759</pub-id><pub-id pub-id-type="pmid">23075127</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Perner</surname><given-names>A</given-names></name><name><surname>Haase</surname><given-names>N</given-names></name><name><surname>Guttormsen</surname><given-names>AB</given-names></name><name><surname>Tenhunen</surname><given-names>J</given-names></name><name><surname>Klemenzson</surname><given-names>G</given-names></name><name><surname>Aneman</surname><given-names>A</given-names></name><name><surname>Madsen</surname><given-names>KR</given-names></name><name><surname>Moller</surname><given-names>MH</given-names></name><name><surname>Elkjaer</surname><given-names>JM</given-names></name><name><surname>Poulsen</surname><given-names>LM</given-names></name><name><surname>Bendtsen</surname><given-names>A</given-names></name><name><surname>Winding</surname><given-names>R</given-names></name><name><surname>Steensen</surname><given-names>M</given-names></name><name><surname>Berezowicz</surname><given-names>P</given-names></name><name><surname>S&#x000f8;e-Jensen</surname><given-names>P</given-names></name><name><surname>Bestle</surname><given-names>M</given-names></name><name><surname>Strand</surname><given-names>K</given-names></name><name><surname>Wiis</surname><given-names>J</given-names></name><name><surname>White</surname><given-names>JO</given-names></name><name><surname>Thornberg</surname><given-names>KJ</given-names></name><name><surname>Quist</surname><given-names>L</given-names></name><name><surname>Nielsen</surname><given-names>J</given-names></name><name><surname>Andersen</surname><given-names>LH</given-names></name><name><surname>Holst</surname><given-names>LB</given-names></name><name><surname>Thormar</surname><given-names>K</given-names></name><name><surname>Kj&#x000e6;ldgaard</surname><given-names>AL</given-names></name><name><surname>Fabritius</surname><given-names>ML</given-names></name><name><surname>Mondrup</surname><given-names>F</given-names></name><name><surname>Pott</surname><given-names>FC</given-names></name><name><surname>M&#x000f8;ller</surname><given-names>TP</given-names></name><name><surname>Winkel</surname><given-names>P</given-names></name><name><surname>Wetterslev</surname><given-names>J</given-names></name><collab>6S Trial Group; Scandinavian Critical Care Trials Group</collab><article-title>Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis</article-title><source>N Engl J Med</source><year>2012</year><volume>367</volume><fpage>124</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1204242</pub-id><pub-id pub-id-type="pmid">22738085</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Barron</surname><given-names>ME</given-names></name><name><surname>Wilkes</surname><given-names>MM</given-names></name><name><surname>Navickis</surname><given-names>RJ</given-names></name><article-title>A systematic review of the comparative safety of colloids</article-title><source>Arch Surg</source><year>2004</year><volume>139</volume><fpage>552</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1001/archsurg.139.5.552</pub-id><pub-id pub-id-type="pmid">15136357</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Guidet</surname><given-names>B</given-names></name><name><surname>Martinet</surname><given-names>O</given-names></name><name><surname>Boulain</surname><given-names>T</given-names></name><name><surname>Philippart</surname><given-names>F</given-names></name><name><surname>Poussel</surname><given-names>JF</given-names></name><name><surname>Maizel</surname><given-names>J</given-names></name><name><surname>Forceville</surname><given-names>X</given-names></name><name><surname>Feissel</surname><given-names>M</given-names></name><name><surname>Hasselmann</surname><given-names>M</given-names></name><name><surname>Heininger</surname><given-names>A</given-names></name><name><surname>Van Aken</surname><given-names>H</given-names></name><article-title>Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study</article-title><source>Crit Care</source><year>2012</year><volume>16</volume><fpage>R94</fpage><pub-id pub-id-type="doi">10.1186/cc11358</pub-id><pub-id pub-id-type="pmid">22624531</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Ickx</surname><given-names>BE</given-names></name><name><surname>Bepperling</surname><given-names>F</given-names></name><name><surname>Melot</surname><given-names>C</given-names></name><name><surname>Schulman</surname><given-names>C</given-names></name><name><surname>Van der Linden</surname><given-names>PJ</given-names></name><article-title>Plasma substitution effects of a new hydroxyethyl starch HES 130/0.4 compared with HES 200/0.5 during and after extended acute normovolaemic haemodilution</article-title><source>Br J Anaesth</source><year>2003</year><volume>91</volume><fpage>196</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1093/bja/aeg159</pub-id><pub-id pub-id-type="pmid">12878617</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Kimme</surname><given-names>P</given-names></name><name><surname>Jannsen</surname><given-names>B</given-names></name><name><surname>Ledin</surname><given-names>T</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Vegfors</surname><given-names>M</given-names></name><article-title>High incidence of pruritus after large doses of hydroxyethyl starch (HES) infusions</article-title><source>Acta Anaesthesiol Scand</source><year>2001</year><volume>45</volume><fpage>686</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1034/j.1399-6576.2001.045006686.x</pub-id><pub-id pub-id-type="pmid">11421825</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Morgan</surname><given-names>PW</given-names></name><name><surname>Berridge</surname><given-names>JC</given-names></name><article-title>Giving long-persistent starch as volume replacement can cause pruritus after cardiac surgery</article-title><source>Br J Anaesth</source><year>2000</year><volume>85</volume><fpage>696</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1093/bja/85.5.696</pub-id><pub-id pub-id-type="pmid">11094582</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Rudolf</surname><given-names>J</given-names></name><article-title>Hydroxyethyl starch for hypervolemic hemodilution in patients with acute ischemic stroke: a randomized, placebo-controlled phase II safety study</article-title><source>Cerebrovasc Dis</source><year>2002</year><volume>14</volume><fpage>33</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1159/000063721</pub-id><pub-id pub-id-type="pmid">12097849</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Waitzinger</surname><given-names>J</given-names></name><name><surname>Bepperling</surname><given-names>F</given-names></name><name><surname>Pabst</surname><given-names>G</given-names></name><name><surname>Opitz</surname><given-names>J</given-names></name><article-title>Hydroxyethyl starch (HES) [130/0.4], a new HES specification: pharmacokinetics and safety after multiple infusions of 10% solution in healthy volunteers</article-title><source>Drugs R D</source><year>2003</year><volume>4</volume><fpage>149</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">12757400</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Wiedermann</surname><given-names>CJ</given-names></name><article-title>Complications of hydroxyethyl starch in acute ischemic stroke and other brain injuries</article-title><source>Pathophysiol Haemost Thromb</source><year>2003</year><volume>33</volume><fpage>225</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1159/000081513</pub-id><pub-id pub-id-type="pmid">15583454</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Woessner</surname><given-names>R</given-names></name><name><surname>Grauer</surname><given-names>MT</given-names></name><name><surname>Dieterich</surname><given-names>HJ</given-names></name><name><surname>Bepperling</surname><given-names>F</given-names></name><name><surname>Baus</surname><given-names>D</given-names></name><name><surname>Kahles</surname><given-names>T</given-names></name><name><surname>Georgi</surname><given-names>S</given-names></name><name><surname>Bianchi</surname><given-names>O</given-names></name><name><surname>Morgenthaler</surname><given-names>M</given-names></name><name><surname>Treib</surname><given-names>J</given-names></name><article-title>Influence of a long-term, high-dose volume therapy with 6% hydroxyethyl starch 130/0.4 or crystalloid solution on hemodynamics, rheology and hemostasis in patients with acute ischemic stroke. Results of a randomized, placebo-controlled, double-blind study</article-title><source>Pathophysiol Haemost Thromb</source><year>2003</year><volume>33</volume><fpage>121</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1159/000077819</pub-id><pub-id pub-id-type="pmid">15170391</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Ridley</surname><given-names>S</given-names></name><name><surname>Morris</surname><given-names>S</given-names></name><article-title>Cost effectiveness of adult intensive care in the UK</article-title><source>Anaesthesia</source><year>2007</year><volume>62</volume><fpage>547</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2044.2007.04997.x</pub-id><pub-id pub-id-type="pmid">17506731</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Perner</surname><given-names>A</given-names></name><name><surname>Haase</surname><given-names>N</given-names></name><name><surname>Wetterslev</surname><given-names>J</given-names></name><name><surname>Aneman</surname><given-names>A</given-names></name><name><surname>Tenhunen</surname><given-names>J</given-names></name><name><surname>Guttormsen</surname><given-names>AB</given-names></name><name><surname>Klemenzson</surname><given-names>G</given-names></name><name><surname>Pott</surname><given-names>F</given-names></name><name><surname>Bodker</surname><given-names>KD</given-names></name><name><surname>Badstolokken</surname><given-names>PM</given-names></name><name><surname>Bendtsen</surname><given-names>A</given-names></name><name><surname>S&#x000f8;e-Jensen</surname><given-names>P</given-names></name><name><surname>Tousi</surname><given-names>H</given-names></name><name><surname>Bestle</surname><given-names>M</given-names></name><name><surname>Pawlowicz</surname><given-names>M</given-names></name><name><surname>Winding</surname><given-names>R</given-names></name><name><surname>B&#x000fc;low</surname><given-names>HH</given-names></name><name><surname>Kancir</surname><given-names>C</given-names></name><name><surname>Steensen</surname><given-names>M</given-names></name><name><surname>Nielsen</surname><given-names>J</given-names></name><name><surname>Fogh</surname><given-names>B</given-names></name><name><surname>Madsen</surname><given-names>KR</given-names></name><name><surname>Larsen</surname><given-names>NH</given-names></name><name><surname>Carlsson</surname><given-names>M</given-names></name><name><surname>Wiis</surname><given-names>J</given-names></name><name><surname>Petersen</surname><given-names>JA</given-names></name><name><surname>Iversen</surname><given-names>S</given-names></name><name><surname>Sch&#x000f8;idt</surname><given-names>O</given-names></name><name><surname>Leivdal</surname><given-names>S</given-names></name><name><surname>Berezowicz</surname><given-names>P</given-names></name><name><surname>Pettil&#x000e4;</surname><given-names>V</given-names></name><name><surname>Ruokonen</surname><given-names>E</given-names></name><name><surname>Klepstad</surname><given-names>P</given-names></name><name><surname>Karlsson</surname><given-names>S</given-names></name><name><surname>Kaukonen</surname><given-names>M</given-names></name><name><surname>Rutanen</surname><given-names>J</given-names></name><name><surname>Karason</surname><given-names>S</given-names></name><name><surname>Kj&#x000e6;ldgaard</surname><given-names>AL</given-names></name><name><surname>Holst</surname><given-names>LB</given-names></name><name><surname>Wernerman</surname><given-names>J</given-names></name><collab>Scandinavian Critical Care Trials Group</collab><article-title>Comparing the effect of hydroxyethyl starch 130/0.4 with balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis (6S--Scandinavian Starch for Severe Sepsis/Septic Shock trial): study protocol, design and rationale for a double-blinded, randomised clinical trial</article-title><source>Trials</source><year>2011</year><volume>12</volume><fpage>24</fpage><pub-id pub-id-type="doi">10.1186/1745-6215-12-24</pub-id><pub-id pub-id-type="pmid">21269526</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Chrispin</surname><given-names>PS</given-names></name><name><surname>Scotton</surname><given-names>H</given-names></name><name><surname>Rogers</surname><given-names>J</given-names></name><name><surname>Lloyd</surname><given-names>D</given-names></name><name><surname>Ridley</surname><given-names>SA</given-names></name><article-title>Short Form 36 in the intensive care unit: assessment of acceptability, reliability and validity of the questionnaire</article-title><source>Anaesthesia</source><year>1997</year><volume>52</volume><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2044.1997.015-az014.x</pub-id><pub-id pub-id-type="pmid">9014540</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Poulsen</surname><given-names>JB</given-names></name><name><surname>Moller</surname><given-names>K</given-names></name><name><surname>Kehlet</surname><given-names>H</given-names></name><name><surname>Perner</surname><given-names>A</given-names></name><article-title>Long-term physical outcome in patients with septic shock</article-title><source>Acta Anaesthesiol Scand</source><year>2009</year><volume>53</volume><fpage>724</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1111/j.1399-6576.2009.01921.x</pub-id><pub-id pub-id-type="pmid">19388891</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Wehler</surname><given-names>M</given-names></name><name><surname>Geise</surname><given-names>A</given-names></name><name><surname>Hadzionerovic</surname><given-names>D</given-names></name><name><surname>Aljukic</surname><given-names>E</given-names></name><name><surname>Reulbach</surname><given-names>U</given-names></name><name><surname>Hahn</surname><given-names>EG</given-names></name><name><surname>Strauss</surname><given-names>R</given-names></name><article-title>Health-related quality of life of patients with multiple organ dysfunction: individual changes and comparison with normative population</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><fpage>1094</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000059642.97686.8B</pub-id><pub-id pub-id-type="pmid">12682478</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Ware</surname><given-names>JE</given-names><suffix>Jr</suffix></name><name><surname>Gandek</surname><given-names>B</given-names></name><name><surname>Kosinski</surname><given-names>M</given-names></name><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Apolone</surname><given-names>G</given-names></name><name><surname>Brazier</surname><given-names>J</given-names></name><name><surname>Bullinger</surname><given-names>M</given-names></name><name><surname>Kaasa</surname><given-names>S</given-names></name><name><surname>Leplege</surname><given-names>A</given-names></name><name><surname>Prieto</surname><given-names>L</given-names></name><name><surname>Sullivan</surname><given-names>M</given-names></name><name><surname>Thunedborg</surname><given-names>K</given-names></name><article-title>The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment</article-title><source>J Clin Epidemiol</source><year>1998</year><volume>51</volume><fpage>1167</fpage><lpage>1170</lpage><pub-id pub-id-type="doi">10.1016/S0895-4356(98)00108-5</pub-id><pub-id pub-id-type="pmid">9817134</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Bjorner</surname><given-names>JB</given-names></name><name><surname>Kreiner</surname><given-names>S</given-names></name><name><surname>Ware</surname><given-names>JE</given-names></name><name><surname>Damsgaard</surname><given-names>MT</given-names></name><name><surname>Bech</surname><given-names>P</given-names></name><article-title>Differential item functioning in the Danish translation of the SF-36</article-title><source>J Clin Epidemiol</source><year>1998</year><volume>51</volume><fpage>1189</fpage><lpage>1202</lpage><pub-id pub-id-type="doi">10.1016/S0895-4356(98)00111-5</pub-id><pub-id pub-id-type="pmid">9817137</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Bjorner</surname><given-names>JB</given-names></name><name><surname>Damsgaard</surname><given-names>MT</given-names></name><name><surname>Watt</surname><given-names>T</given-names></name><name><surname>Groenvold</surname><given-names>M</given-names></name><article-title>Tests of data quality, scaling assumptions, and reliability of the Danish SF-36</article-title><source>J Clin Epidemiol</source><year>1998</year><volume>51</volume><fpage>1001</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.1016/S0895-4356(98)00092-4</pub-id><pub-id pub-id-type="pmid">9817118</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="book"><name><surname>Ware</surname><given-names>JE</given-names></name><name><surname>Snow</surname><given-names>KK</given-names></name><name><surname>Kosinski</surname><given-names>M</given-names></name><name><surname>Gandek</surname><given-names>B</given-names></name><source>SF-36 Health Survey: Manual and Interpretation Guide</source><year>1993</year><publisher-name>Boston: The Health Institute, New England Medical Center</publisher-name></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Pillebout</surname><given-names>E</given-names></name><name><surname>Nochy</surname><given-names>D</given-names></name><name><surname>Hill</surname><given-names>G</given-names></name><name><surname>Conti</surname><given-names>F</given-names></name><name><surname>Antoine</surname><given-names>C</given-names></name><name><surname>Calmus</surname><given-names>Y</given-names></name><name><surname>Glotz</surname><given-names>D</given-names></name><article-title>Renal histopathological lesions after orthotopic liver transplantation (OLT)</article-title><source>Am J Transplant</source><year>2005</year><volume>5</volume><fpage>1120</fpage><lpage>1129</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2005.00852.x</pub-id><pub-id pub-id-type="pmid">15816895</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Christidis</surname><given-names>C</given-names></name><name><surname>Mal</surname><given-names>F</given-names></name><name><surname>Ramos</surname><given-names>J</given-names></name><name><surname>Senejoux</surname><given-names>A</given-names></name><name><surname>Callard</surname><given-names>P</given-names></name><name><surname>Navarro</surname><given-names>R</given-names></name><name><surname>Trinchet</surname><given-names>JC</given-names></name><name><surname>Larrey</surname><given-names>D</given-names></name><name><surname>Beaugrand</surname><given-names>M</given-names></name><name><surname>Guettier</surname><given-names>C</given-names></name><article-title>Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions</article-title><source>J Hepatol</source><year>2001</year><volume>35</volume><fpage>726</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1016/S0168-8278(01)00200-8</pub-id><pub-id pub-id-type="pmid">11738099</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Schmidt-Hieber</surname><given-names>M</given-names></name><name><surname>Loddenkemper</surname><given-names>C</given-names></name><name><surname>Schwartz</surname><given-names>S</given-names></name><name><surname>Arntz</surname><given-names>G</given-names></name><name><surname>Thiel</surname><given-names>E</given-names></name><name><surname>Notter</surname><given-names>M</given-names></name><article-title>Hydrops lysosomalis generalisatus--an underestimated side effect of hydroxyethyl starch therapy?</article-title><source>Eur J Haematol</source><year>2006</year><volume>77</volume><fpage>83</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0609.2006.00657.x</pub-id><pub-id pub-id-type="pmid">16608502</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="other"><collab>Department Of Health &#x00026; Human Services</collab><article-title>NDA review memo (mid-cycle)</article-title><ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/NewDrugApplicationsNDAs/UCM083393.pdf">http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/NewDrugApplicationsNDAs/UCM083393.pdf</ext-link></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Reich</surname><given-names>A</given-names></name><name><surname>Stander</surname><given-names>S</given-names></name><name><surname>Szepietowski</surname><given-names>JC</given-names></name><article-title>Drug-induced pruritus: a review</article-title><source>Acta Derm Venereol</source><year>2009</year><volume>89</volume><fpage>236</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.2340/00015555-0650</pub-id><pub-id pub-id-type="pmid">19479118</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Stander</surname><given-names>S</given-names></name><name><surname>Bone</surname><given-names>HG</given-names></name><name><surname>Machens</surname><given-names>HG</given-names></name><name><surname>Aberle</surname><given-names>T</given-names></name><name><surname>Burchard</surname><given-names>W</given-names></name><name><surname>Prien</surname><given-names>T</given-names></name><name><surname>Luger</surname><given-names>TA</given-names></name><name><surname>Metze</surname><given-names>D</given-names></name><article-title>Hydroxyethyl starch does not cross the blood-brain or the placental barrier but the perineurium of peripheral nerves in infused animals</article-title><source>Cell Tissue Res</source><year>2002</year><volume>310</volume><fpage>279</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1007/s00441-002-0644-6</pub-id><pub-id pub-id-type="pmid">12457226</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Heyland</surname><given-names>DK</given-names></name><name><surname>Hopman</surname><given-names>W</given-names></name><name><surname>Coo</surname><given-names>H</given-names></name><name><surname>Tranmer</surname><given-names>J</given-names></name><name><surname>McColl</surname><given-names>MA</given-names></name><article-title>Long-term health-related quality of life in survivors of sepsis. Short Form 36: a valid and reliable measure of health-related quality of life</article-title><source>Crit Care Med</source><year>2000</year><volume>28</volume><fpage>3599</fpage><lpage>3605</lpage><pub-id pub-id-type="doi">10.1097/00003246-200011000-00006</pub-id><pub-id pub-id-type="pmid">11098960</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Little</surname><given-names>RJ</given-names></name><name><surname>D'Agostino</surname><given-names>R</given-names></name><name><surname>Cohen</surname><given-names>ML</given-names></name><name><surname>Dickersin</surname><given-names>K</given-names></name><name><surname>Emerson</surname><given-names>SS</given-names></name><name><surname>Farrar</surname><given-names>JT</given-names></name><name><surname>Frangakis</surname><given-names>C</given-names></name><name><surname>Hogan</surname><given-names>JW</given-names></name><name><surname>Molenberghs</surname><given-names>G</given-names></name><name><surname>Murphy</surname><given-names>SA</given-names></name><name><surname>Neaton</surname><given-names>JD</given-names></name><name><surname>Rotnitzky</surname><given-names>A</given-names></name><name><surname>Scharfstein</surname><given-names>D</given-names></name><name><surname>Shih</surname><given-names>WJ</given-names></name><name><surname>Siegel</surname><given-names>JP</given-names></name><name><surname>Stern</surname><given-names>H</given-names></name><article-title>The prevention and treatment of missing data in clinical trials</article-title><source>N Engl J Med</source><year>2012</year><volume>367</volume><fpage>1355</fpage><lpage>1360</lpage><pub-id pub-id-type="doi">10.1056/NEJMsr1203730</pub-id><pub-id pub-id-type="pmid">23034025</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Hays</surname><given-names>RD</given-names></name><name><surname>Woolley</surname><given-names>JM</given-names></name><article-title>The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it?</article-title><source>Pharmacoeconomics</source><year>2000</year><volume>18</volume><fpage>419</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.2165/00019053-200018050-00001</pub-id><pub-id pub-id-type="pmid">11151395</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Samsa</surname><given-names>G</given-names></name><name><surname>Edelman</surname><given-names>D</given-names></name><name><surname>Rothman</surname><given-names>ML</given-names></name><name><surname>Williams</surname><given-names>GR</given-names></name><name><surname>Lipscomb</surname><given-names>J</given-names></name><name><surname>Matchar</surname><given-names>D</given-names></name><article-title>Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II</article-title><source>Pharmacoeconomics</source><year>1999</year><volume>15</volume><fpage>141</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.2165/00019053-199915020-00003</pub-id><pub-id pub-id-type="pmid">10351188</pub-id></mixed-citation></ref></ref-list></back></article>